A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
Rabab Mohamed Gaafar, Veerle F.M. Surmont, Giorgio V. Scagliotti et al. · European Journal of Cancer · 2011
Cited by 120 works. doi:10.1016/j.ejca.2011.06.045
Authors
- Rabab Mohamed Gaafar
- Veerle F.M. Surmont
- Giorgio V. Scagliotti
- Rob J. van Klaveren
- Demetris Papamichael
- Baktiar Hasan
- Valter Torri
- Jan P. van Meerbeeck
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Estimates of the cancer incidence and mortality in Europe in 2006
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial